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Abstract
Objective The objective of the study is to investigate the
electrocortical and the global cognitive effects of 3 months
rivastigmine medication in a group of mild to moderate
Alzheimer’s disease patients.
Materials and methods Multichannel EEG and cognitive
performances measured with the Mini Mental State Exam-
ination in a group of 16 patients with mild to moderate
Alzheimer’s Disease were collected before and 3 months
after the onset of rivastigmine medication.
Results Spectral analysis of the EEG data showed a
significant power decrease in the delta and theta frequency
bands during rivastigmine medication, i.e., a shift of the
power spectrum towards ‘normalization’. Three-dimensional
low resolution electromagnetic tomography (LORETA)
functional imaging localized rivastigmine effects in a
network that includes left fronto-parietal regions, posterior
cingulate cortex, bilateral parahippocampal regions, and the
hippocampus. Moreover, a correlation analysis between
differences in the cognitive performances during the two
recordings and LORETA-computed intracortical activity
showed, in the alpha1 frequency band, better cognitive
performance with increased cortical activity in the left insula.
Conclusion The results point to a ‘normalization’ of the
EEG power spectrum due to medication, and the intra-
cortical localization of these effects showed an increase of
cortical activity in frontal, parietal, and temporal regions
that are well-known to be affected in Alzheimer’s disease.
The topographic convergence of the present results with
the memory network proposed by Vincent et al. (J.
Neurophysiol. 96:3517–3531, 2006) leads to the speculation
that in our group of patients, rivastigmine specifically
activates brain regions that are involved in memory functions,
notably a key symptom in this degenerative disease.
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Introduction
Alzheimers’s disease (AD) is a degenerative process,
characterized by the loss of cholinergic neurons in the
basal forebrain nuclei (Whitehouse et al. 1981). This
degeneration of cortical projection of cholinergic neurons
results in a deficiency of acetylcholine in the neocortex and
hippocampus (Geula 1998), and the deficit is, to some
extent, responsible for the underlying cognitive and
neuropsychiatric dysfunction.
Based on the cholinergic hypothesis, cholinesterase
inhibitors (ChE-I) currently is the most frequently recom-
mended symptomatic treatment (Doody et al. 2001).
Clinical studies have confirmed the efficacy of ChE-I
treatment in AD on cognitive and neuropsychiatric symptoms
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(see Bullock and Dengiz 2005, for a review) and a series of
recent positron emission tomography (PET) and single
photon emission computed tomography (SPECT) studies
reported an increase of cortical activity due to ChE-I therapy
at temporo-parietal and frontal regions (e.g., Bohnen et al.
2005; Ceravolo et al. 2004; Mega et al. 2001), in the
hippocampus (Mega et al. 2001), and in the posterior
cingulum (Bohnen et al. 2005; Ceravolo et al. 2004), i.e.,
in regions that have been shown to be the most affected
cortical areas in AD (e.g., Jagust et al. 1997).
Because electroencephalography (EEG), as a noninvasive
method, can be applied repeatedly, it is a suitable tool to assess
the course of the cortical activity during psychoactive
medication. The spontaneous EEG, i.e., the recording of the
brain electrical activity during resting, is a standard procedure.
It is well established that patients with clinically diagnosed
AD show a slowing of their EEG frequency during resting
compared with healthy age-matched subjects: AD patients
have increased power in slow frequency EEG activity (delta
and theta frequency bands) and decreased power in fast
frequency EEG activity (alpha and beta frequency bands; e.g.,
Gianotti et al. 2007; Schreiter-Gasser et al. 1993). Moreover,
EEG has also been shown to reflect the progressive cortical
dysfunctioning correlated with the cognitive impairment in
AD patients (e.g., Gianotti et al. 2007; Schreiter-Gasser et al.
1994).
Relationships between cholinergic system and EEG
power spectrum, especially in slow EEG frequencies, have
been recognized in a variety of animal (e.g., Crouzier et al.
2006; Keita et al. 2000) and human studies (e.g., Riekkinen
et al. 1991; Hartikainen et al. 1992). Treatment with ChE-I
has been shown to decrease the amount of slow EEG
activity, i.e., to ‘normalize’ the EEG power spectrum (e.g.,
Adler and Brassen 2001; Balkan et al. 2003; Jelic et al.
1998; Kogan et al. 2001).
Unfortunately, single or multichannel EEG has the
limitation that the signals that are measured on the head
surface do not directly indicate the location of the active
neuronal generators in the brain. To solve this so-called
‘inverse problem’, the three-dimensional source localization
method, low resolution electromagnetic tomography
(LORETA, Pascual-Marqui et al. 1994, 1999), was used.
Using this method, Babiloni and colleagues showed
correlations in the EEG delta and alpha frequency bands
between the strength of the intracerebral sources and the
severity of global cognitive decline (Babiloni et al. 2006a),
and the severity of focused attention decline (Babiloni et al.
2007). Of particular interest for the present investigation is
the only previous LORETA ChE-I treatment study done by
Babiloni et al. (2006b): Globally, they did not show any
significant shift towards normalization in the cortical
activity after 1 year of donepezil treatment, but dividing
their AD subjects into two groups based on their cognitive
performance differences (‘responders’ vs. ‘nonresponders’),
the authors found that ‘responders’ showed a lesser reduction
of occipital and temporal alpha1 activity compared to
nonresponders, thus pointing to a correlation between the
difference of cognitive performances and the difference of
alpha1 cortical activity after 1 year of donepezil treatment.
All these LORETA studies used a macroregion rather
than a voxel-wise approach, thus reducing the number of
statistical tests but forgoing a higher spatial resolution.
Using a voxel-wise approach, a previous LORETA
functional imaging study on a group of non-medicated
mild to moderate AD patients specified that increases in
slow frequency EEG activity (delta and theta frequency
bands) and decreases in fast frequency EEG activity
(alpha2, beta1, beta2, and beta3 frequency bands) affected
different cortical areas while largely sparing prefrontal
cortex (Gianotti et al. 2007); the study also showed that
decreased delta activity at left parietal areas and increased
alpha1 activity at left temporal areas correlated with better
cognitive performance measured with the Mini Mental
State Examination (MMSE, Folstein et al. 1975).
In the present study, multichannel EEG was recorded in
a group of 16 AD patients at baseline and after 3 months of
rivastigmine treatment to monitor the electrocortical effects
of ChE-I using LORETA functional imaging. A group of
16 matched controls was also recorded to confirm the
typical reported aberrations of AD resting EEG (see above).
Based on the studies reviewed above, we hypothesized
that our patients under rivastigmine will show a ‘normal-
ization’ of their power spectrum on the scalp, particularly a
decrease of slow frequency activity and an increase of
cortical activity at temporo-parietal, frontal, cingulate, and
hippocampal regions. Furthermore, we hypothesized that
the expected cognitive amelioration under rivastigmine will
positively correlate with an increase of cortical activity
localized in left-lateralized temporo-parietal areas as pre-
dicted by our earlier LORETA study reviewed above.
Materials and methods
Subjects
Sixteen patients with clinically diagnosed AD (mean age:
77.4 years, S.D.: 6.2; eight men and eight women;
handedness: 5 right, 11 unknown) admitted to the Depart-
ment of Geriatric Psychiatry at the University Hospital of
Zurich, Switzerland, took part in the study. All patients met
the diagnosis of probable or possible AD according to the
NINCDS-ADRDA (McKahnn et al. 1984) criteria and the
ICD-10 Classification of Mental and Behavioral Disorders
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(WHO 1993). Patients with possible vascular dementia,
mixed AD-vascular dementia, and major depression were
ruled out by neuropsychological testing, laboratory inves-
tigations, and brain structural imaging (computed tomogra-
phy or magnetic resonance tomography). All patients were
enrolled for the participation in an open-label treatment
study with rivastigmine. The first, baseline EEG was
recorded before rivastigmine therapy (session t0). The
second, follow-up EEG recording was done 3 months after
treatment initiation (session t1). In all patients, other
centrally active medication was terminated 1 week before
the EEG recordings. MMSE was administered at the
beginning of both recording sessions to assess the severity
of the disease and to monitor cognitive changes due to the
medication. A group of 16 age- and gender-matched
healthy volunteers was used as controls (mean
age=74.0 years, S.D=8.5). Cognitive impairment was
excluded by clinical interviews and neuropsychological
testing. The study was approved by the Ethics Committee
of the University Hospital Zurich. Written informed consent
was obtained from all subjects.
EEG recordings
Vigilance-controlled multichannel EEG was recorded using
a Nihon-Kohden “NeuroFile” system (electrode impedance
<5 kOhm, 1–120 Hz bandpass, 256 samples/s). Nineteen
electrodes covering the entire scalp were placed according
to the International 10-20 System (Nuwer et al. 1998) at the
following locations: Fp1/2, F7/8, F3/4, FZ, T3/4, C3/4, CZ,
T5/6, P3/4, Pz, O1/2. The average of F3 and F4 was used as
recording reference. Electrodes at the left outer canthus and
above and below the left eye were used to monitor vertical
and horizontal eye movements. Subjects were seated in a
sound- and electrically shielded chamber with dim illumi-
nation. They were instructed that the experiment involved
EEG recording during resting with open or closed eyes. The
instructions about eye opening/closing were given via
intercom. The following protocol was used for every
subject: (1) 20 s eyes open, 20 s eyes closed; (2) 20 s eyes
open, 80 s eyes closed; (3) 20 s eyes open, 80 s eyes closed;
(4) 20 s eyes open, 20 s eyes closed. Only data from the
total of 200 s eyes closed conditions were analyzed.
For each subject, the EEG recordings were carefully
inspected off-line on a PC display for artifacts caused by eye
and head movements, muscle activity, sweating, and
technical problems. Using a moving, nonoverlapping win-
dow, all artifact-free 2-s epochs were selected for further
analyses. On the average across patients and sessions, there
were 20.3 (SD=1.5) 2-s epochs available, and across controls
there were 19.7 (SD=2.0), with no significant difference
between the two sessions and between groups.
EEG data analysis
Spectral analysis
The EEG data were recomputed against the average
reference (Lehmann and Skrandies 1980). Fast Fourier
Transformation (FFT using a square window) was applied
to each epoch and channel to compute the spectral power
density with 0.5-Hz frequency resolution. For each subject
and for each session, the spectra for each channel were
averaged over all epochs.
For descriptive statistics, mean power values over
subjects were computed for each session.
Absolute spectral power values for each subject, session,
and channel were integrated for the following seven
independent frequency bands (Kubicki et al. 1979): delta
(1.5–6 Hz), theta (6.5–8 Hz), alpha1 (8.5–10 Hz), alpha2
(10.5–12 Hz), beta1 (12.5–18 Hz), beta2 (18.5–21 Hz), and
beta3 (21.5–30 Hz). Before statistical analysis, log trans-
formation was applied to normalize the distribution of
absolute power values (Gasser et al. 1982).
A two-way analysis of variance (ANOVA) with groups
(2 levels: AD patients and controls at time t0) as between-
subject factor and electrode location (19 levels: Fp1/2, F7/8,
F3/4, FZ, T3/4, C3/4, CZ, T5/6, P3/4, Pz, O1/2) as within-
subject factor was carried out for each frequency band
separately.
Subsequently, only for the AD group, a two-way
ANOVA with session (two levels: t0 and t1) and electrode
location (19 levels: Fp1/2, F7/8, F3/4, FZ, T3/4, C3/4, CZ,
T5/6, P3/4, Pz, O1/2) as within-subject factors was carried
out for each frequency band separately. Paired t tests were
used as post hoc tests. Throughout, two-tailed p values are
reported.
The MMSE data were normally distributed according to
the Shapiro–Wilk test. Correlations between differences in
power density in the seven frequency bands (session t1−
session t0) and differences in the clinical severity measured
with the MMSE (session t1−session t0) were computed
using Pearsons’ product-moment correlations.
LORETA functional images of electric neuronal activity
From scalp-recorded electric potentials, LORETA
(Pascual-Marqui et al. 1994, 1999) estimates the distribu-
tion of electric source activity by assuming similar
activation among neighboring neuronal ensembles, an
assumption implemented by computing the ‘‘smoothest’’
of all possible activity distributions.
This three-dimensional source localization technique has
recently received important cross-modal validation from
studies combining LORETA with functional magnetic
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resonance imaging (MRI; Mulert et al. 2004), structural MRI
(Worrell et al. 2000), and PET (Oakes et al. 2004).
Especially concerning AD, it has been shown that the spatial
pattern of glucose metabolism correlates with the localiza-
tion of intracerebral EEG generators (Dierks et al. 2000).
The version of LORETA that was implemented in the
present study uses a three-shell spherical head model that
includes scalp, skull, and brain compartments. EEG electrode
coordinates were derived from cross-registrations between
spherical and realistic head geometry (Towle et al. 1993). Both
the head model and the electrode coordinates were coregis-
tered to the Talairach brain atlas (Talairach and Tournoux
1988), digitized at the Brain Imaging Center of the Montreal
Neurological Institute (MNI305; Collins et al. 1994). The
source space (2,394 voxels at a voxel size of 7×7×7 mm) was
restricted to cortical gray matter and hippocampi as defined by
the digitized MNI probability atlas. The LORETA functional
images represent the electrical activity at each voxel as
squared magnitude (i.e., power) of computed current density
(unit: amperes per square meter, A/m2).
The recorded scalp electric potentials were used for
computing the LORETA functional images. These func-
tional images were computed for each subject separately,
for the seven classical frequency bands (for technical
details, see Frei et al. 2001).
The localization of the differences in activity between the
two sessions in the seven frequency bands was assessed with
voxel-by-voxel paired t tests of the log-transformed com-
puted current density power. In addition, global, widespread
differences (cluster analysis) were assessed by applying the
exceedance proportion test (Friston et al. 1990). In all
cases, the nonparametric randomization approach (Nichols
and Holmes 2002) was used for estimating empirical
probability distributions and the corresponding corrected
(for multiple comparisons) critical probability thresholds.
Furthermore, for each of the seven frequency bands,
Pearsons’ product-moment correlations between differences
in current density (session t1−session t0) and differences in
the clinical severity measured with the MMSE (session
t1−session t0) were computed.
Results
Cognitive impairment
The cognitive impairment was assessed with the MMSE
where scores range from 0 to 30, the optimum. All controls
had an MMSE score of 30. The MMSE scores of the AD
patients at t0 (i.e., without rivastigmine medication) ranged
between 10 and 27 (mean=19.1; SD=5.7), and was
significantly lower compared to those of the controls (p<
0.001). At t1, the MMSE scores ranged between 10 and 29
(mean=19.2; SD=5.8): seven patients showed an improve-
ment of their MMSE scores (mean score difference=+3.1
points; SD=2.41), and eight patients showed a worsening in
their MMSE scores (mean score difference=−2.6 points;
SD=2.07). One patient showed no difference between the
two sessions. Across all patients, there was no difference of
the MMSE scores between the two sessions. Table 1 shows
the patient characteristics and MMSE scores at baseline and
at the 3-months follow-up.
Spectral analysis
The comparison of the band power between the two groups
at session t0, established the expected slowing of EEG
frequencies in the AD patients: delta and theta increased
significantly (F(1,30)=6.73, p=0.015; F(1,30)=9.32,
p=0.005), and beta3 decreased significantly (F(1,30)=5.53,
p=0.026) in AD patients compared to controls. Having
confirmed the abnormal power spectrum of the AD patients,
we focused on the rivastigmine effects in AD disease.
For AD patients, Fig. 1 exhibits the log-transformed
mean power spectra across the 19 channels for sessions t0
and t1 (panel a), the mean values and 95% confidence
interval for the difference between sessions (panel b), and
their corresponding p values at each frequency bin (panel c).
The power spectrum of the AD patients in session t1
evidently shows lower values in the delta and theta
frequency range. In the faster frequency range, the two
distributions overlap, denoting similar values between the
two sessions.
Comparing absolute band power between the two
sessions, there was a significant decrease in delta (F(1,15)=
6.94, p=0.019) and in theta (F(1,15)=7.27, p=0.017) in
session t1 compared to t0. No significant changes were
observed for the other frequency bands. There were no
significant interactions between session X electrode location
for delta or theta power. Figure 2 illustrates the significant
differences of the follow-up t tests for the 19 channels:
significant lower values in t1 were observed for delta at ten
channels and for theta at eight channels.
The computation of correlations between differences in
frequency band power and differences in the MMSE scores
between sessions t0 and t1 did not yield significant results.
The smallest p value was reached in the delta frequency
band (r=−0.40, p=0.13).
LORETA functional images of electric neuronal activity
The LORETA image statistics showed significant differ-
ences in cortical activity between the two sessions in two of
the seven frequency bands, the two slow frequency bands
of delta and theta. Figure 3 illustrates the brain areas where
the AD patients had significantly weaker activity in session
t1 compared to session t0 in these bands.
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In the delta band, the cluster analysis resulted in the
identification of three large clusters that reached p=0.016
(corrected). The largest cluster was localized at left-
lateralized fronto-parietal regions. Voxel-by-voxel analysis
in this cluster yielded p<0.05 (corrected) in Brodmann
Area (BA) 7 and BA 40 (superior parietal and inferior
parietal, respectively). The second significant cluster
grouped voxels at central parietal and cingulate regions,
where the voxel-by-voxel analysis yielded p<0.05 (corrected)
in BA 7 (precuneus). The third cluster included para-
hippocampal regions and the hippocampus bilaterally, where
the voxel-by-voxel analysis yielded p<0.05 (corrected) in
hippocampus and BA 36 (parahippocampal region).
In the theta band, a unique large cluster (p=0.021,
corrected) at left-lateralized fronto-parietal regions was
identified. Voxel-by-voxel analysis in this cluster yielded
p<0.03 (corrected) in BAs 4, 7 and 40 (precentral, superior
and inferior parietal lobule, respectively).
Table 2 gives a complete listing of all BAs that contained
significantly different LORETA voxels.
Figure 4 displays the LORETA results in the alpha1 band
that showed significant correlations between voxel current
density and MMSE scores. The alpha1 band showed positive
correlations in the left insula with a maximum in BA 13
(r=0.57, p=0.02), indicating better cognitive performance
with increased alpha1 band power in this area.
Discussion
Four main findings have emerged from the present study.
The first finding is that before rivastigmine treatment, the
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Fig. 1 Power spectra before and
3 months after rivastigmine
therapy. a The log-transformed
mean absolute power spectra
across the 19 channels of the
two sessions; b mean values
(black line) and 95% confidence
interval (grey area) for the dif-
ference between sessions, and c
their corresponding p values at
each frequency bin
Table 1 Patient characteristics and MMSE scores at baseline and
3 months after the onset of rivastigmine medication
Subject Gender (M/F) Age (years) MMSE Score
baseline follow-up
1 M 64 19 17
2 M 70 15 17
3 F 72 14 13
4 M 74 22 25
5 M 75 25 29
6 F 75 15 16
7 F 77 20 14
8 F 77 15 23
9 F 77 10 10
10 M 78 26 21
11 F 78 25 24
12 F 80 24 20
13 M 82 11 10
14 M 84 27 26
15 F 85 24 25
16 M 90 14 17
Mean±SD 77.4±6.2 19.1±5.7 19.2±5.8
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16 mild to moderate AD patients compared with their
matched controls showed the expected slowing of their
EEG frequency, i.e., increased power in slow frequency
EEG activity (delta and theta frequency bands) and
decreased power in fast frequency EEG activity (beta3
frequency band), in keeping with previous quantitative
EEG results (e.g., Gianotti et al. 2007; Schreiter-Gasser et
al. 1993), and thus validating the AD diagnosis of our
patients from the electrophysiological perspective.
The other three findings concern the effects of 3 months
of rivastigmine treatment in the AD patients, monitored
with the MMSE that assessed global cognitive perfor-
mance, and with the spontaneous EEG.
The global cognitive performance of the AD patients
showed no significant differences between the two sessions,
thus confirming the stabilizing effect of 3 months of
rivastigmine on cognitive performances (e.g., Almkvist et
al. 2004). In fact, the typical annual decline in untreated
patients has been reported to be two to four points on the
MMSE (Bullock and Dengiz 2005). Specifically, 8 of our
16 AD patients cognitively benefited from the treatment, in
line with previous observations that a positive response to
the medication occurs on average in 30–70% of treated
patients (e.g., Farlow et al. 2000; Feldman and Lane 2007).
Confirming our first hypothesis on spontaneous EEG,
spectral analysis of the EEG data showed a significant power
decrease in the delta and theta frequency bands during
rivastigmine in our AD patients. These results agree with
previous quantitative EEG studies that showed a shift of the
power spectral EEG towards ‘normalization’. In particular,
after short-term (5 days to 2 weeks) rivastigmine treatment,
three previous studies showed a decrease of delta (Adler and
Brassen 2001) and of theta (Adler and Brassen 2001; Adler
et al. 2004; Brassen and Adler 2003). To our knowledge, the
present paper is the first long-term (3 months) study that
used rivastigmine and that reports a stabilization of these
electrophysiological effects. Long-term studies conducted
with other ChE-I (donepezil: Balkan et al. 2003; Kogan et al.
2001; tacrine: Jelic et al. 1998) also reported a ‘normaliza-
tion’ of slow EEG frequency in AD patients.
Confirming our second hypothesis, LORETA localized
long-term rivastigmine effects in a network that includes
1
External view
LH
Mesial view Mesial view
LH
External view
RH RH
Bottom view
delta
theta
1 2 2
3
33
Fig. 3 LORETA-based statistical nonparametric maps (SnPM) illus-
trating the differences at p<0.05 (corrected for multiple testing) of
LORETA current density between the two sessions t0 and t1 in delta
(upper part) and theta (lower part). Results are displayed on the
‘fiducial cortical surface’ (boundary midway through cortical thick-
ness, Dickson et al. 2001). LH Left hemisphere, RH right hemisphere,
A anterior, P posterior, R right, L left. Cortex shown in gray scale;
decreased activity in session t1 compared to t0 in red. Cluster no. 1:
left fronto-parietal regions (light blue); cluster no. 2: central parietal
and cingulate regions (pink), cluster no. 3: parahippocampal regions
and the hippocampus (light green)
Delta Theta
-4
+4
t-value
<  p < 0.05
<  p < 0.05
0
Fig. 2 T-maps illustrating the differences of EEG frequency band
power between the two sessions t0 and t1 in delta and theta. Head seen
from above, left ear left, nose up; the 19 electrode positions are
indicated by open symbols. t values are color-coded in steps of t=1
(see calibration scale). Decreased EEG power in session t1 compared
to t0 in red
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three spatial clusters in frontal, parietal, and temporal
regions. Specifically, during medication, left fronto-parietal
regions showed a significant decrease of delta and theta
frequency activity. Moreover, delta activity significantly
decreased in the posterior cingulate cortex, and bilateral in
parahippocampal regions and in hippocampus. We note that
a decrease of delta and theta activity corresponds to an
increase of cortical activation in the concerned regions
(Buchan et al. 1997).
AD patients compared to healthy controls consistently
showed decreased activity in medial temporal lobe structures
such as parahippocampal regions and in the hippocampus as
shown in fMRI studies (e.g., Celone et al. 2006; Machulda
et al. 2003; Small et al. 1999) and in SPECT and PET
studies (e.g., Bradley et al. 2002; see Matsuda 2001, for a
review). Medial temporal lobe structures and the hippo-
campus are among the first regions targeted by AD
pathology (Braak and Braak 1991) and are key regions
for memory functions, especially episodic memory, whose
impairment is the hallmark of early AD (Hyman et al.
1984). Reduced metabolism in the posterior cingulate
cortex and precuneus are also a common finding in early
AD (Bradley et al. 2002; Matsuda 2001; Minoshima et al.
1997).
The present results demonstrate an increase of cortical
activity due to rivastigmine medication in regions that are
well known to be affected in AD already at an early stage
of the disease. In line with our EEG-based results, a series
of PET and SPECT studies demonstrated hypermetabolism
or hyperperfusion after ChE-I medication in AD patients in
fronto-parietal regions (Bohnen et al. 2005; Ceravolo et al.
2004; Mega et al. 2001; Stefanova et al. 2006), in posterior
cingulate (Bohnen et al. 2005; Ceravolo et al. 2004), and in
parahippocampal or hippocampal regions (Mega et al. 2001).
The cortical regions that were affected by rivastigmine
medication in the present study overlap with the recently
proposed hippocampal-parietal memory network (Vincent
et al. 2006). Vincent et al. (2006) were concerned with the
hypothesis that parietal cortex contains areas associated
with the medial temporal lobe memory system. In their
fMRI study, they examined correlations in spontaneous
BOLD fluctuations in different brain areas. This novel
approach focused on the surprising observation that
spontaneous activity at resting state (i.e., in the absence of
overt task performance) consistently and repeatedly exhibits
a coactivation in a distributed network of cortical regions,
the so-called default-mode networks (e.g., Gusnard and
Raichle 2001; Raichle et al. 2001).
The topographic convergence of our results with the
memory network proposed by Vincent et al. (2006) leads to
the speculation that rivastigmine in our AD patients
specifically activates brain regions that are involved in
Table 2 Voxels of interest of the LORETA-based statistical nonpara-
metric maps for assessing differences of activation between sessions t0
and t1 in AD patients in 2 EEG frequency bands
BA# LH LH
1 -  - 1  -
2  - 1  -
3  - 5  -
4  - 6  -
5 3 3  -
6 21  - 5  -
7 65 23 22  -
8  - -  - -
9  - -  - -
10  - -  - -
11  - -  - -
12  - -  - -
13  - -  - -
14  - -  - -
15  - -  - -
16  - -  - -
17  - -  - -
18  - -  - -
19 3  -  -  -
20 2 3  -  -
21  - -  - -
22  - -  - -
23 1 1  -  -
24  - -  - -
25  - -  - -
26  - -  - -
27 1 1  -  -
28  - -  - -
29 1 1  -  -
30 3  -  -
31 11 10  -  -
32  - -  - -
33  - -  - -
34  - -  - -
35 4 3  -  -
36 9 9  -  -
37 4 2  -  -
38  - -  - -
39 1  -  -  -
40 42  - 32  -
41  - -  - -
42  - -  - -
43  - -  - -
44  - -  - -
45  - -  - -
46  - -  - -
47  - -  - -
hipp. 6 5  -  -
TOTAL 196 61 75 0
thetadelta
RH RH
7
8
4
3
The number of voxels sorted by Brodmann areas (BA number, first
column) are listed separately for the left (LH) and for the right
hemisphere (RH). Colors mark the different clusters, and refer to
Fig. 3.
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memory functions, notably a key symptom in this degen-
erative disease.
To our knowledge, this is the second EEG LORETA-
based study focusing on ChE-I effects in AD. The other
study (Babiloni et al. 2006b) did not show any shift towards
normalization in the cortical activity after 1 year of
donepezil. Contrary, they reported a significant increase in
the slow delta and theta frequencies and a significant
decrease in the alpha band after treatment. These observa-
tions actually indicate a progressive cortical degeneration
during the study year despite of the treatment. The reason
of the discrepant results between the two EEG LORETA
studies is probably in part to refer to the different durations
of the studies: AD is a progressive disease and even if ChE-
I treatment has been reported to be useful in psychological
and in physiological measurements, it is to be assumed that
the degeneration of cortical projection of cholinergic
neurons will progress, and therefore, after a certain time,
the initial benefits of the treatment will vanish. Neverthe-
less, Babiloni et al. (2006b) reported a less dramatic
decrease of activity in the alpha1 band in occipital and
temporal regions in the group of AD patients that were
recognized as ‘responders’ (based on the MMSE scores)
compared to the ‘nonresponders’. This result is particularly
interesting and very in line with the correlation results
reported in the present study. Our data showed a significant
correlation in the alpha1 band between the differences in
the cognitive functions measured with MMSE during the
two sessions and LORETA-computed intracortical activity
in the left insula, indicating better cognitive performance
with increased alpha1 current density.
A previous study by our group found that in a group of
non-medicated mild to moderate AD, increased alpha1
activity in left temporal cortical areas was associated with
better cognitive performances (Gianotti et al. 2007). It is
worthy to note that, the insula is strongly reciprocally
interconnected with temporal regions (Shelley and Trimble
2004). A volumetric MRI study showed that mild to
moderate AD patients have significantly more atrophy of
the insula (together with the hippocampus and the parietal
cortex) than healthy age-matched controls (Foundas et al.
1997). PET studies in healthy subjects have found that the
activation of the insula was associated with verbal memory
tasks (Grasby et al. 1994; Paulesu et al. 1993). Of particular
interest for the present results, verbal memory impairment
was shown after left but not right insular cortex infarction
(Manes et al. 1999). It appears that the left insula is part of
a functional neuroanatomical circuit that is involved in
verbal (semantic) memory and that is impaired in AD.
Based on the present results, we speculated that AD
patients that cognitively benefited from medication—
possibly via a reduction of verbal memory impairment—
showed an increase of alpha1 EEG activity in the left insula.
In light of the present EEG results, the lack of a statistical
significant global cognitive amelioration measured with the
MMSE, might appear surprising at first sight. There are some
indications that treatment with ChE-I not only stabilizes
cognitive function in a global sense, but also has positive
effects on specific cognitive functions such as attention
rather than episodic memory (tacrine medication, Almkvist
et al. 2001). As said above, we speculated based on the
present neuroimaging results that rivastigmine possibly
reduces the verbal memory impairment of mild to moderate
AD patients. Future studies that combine neurophysiological
measurements with cognitive/neuropsychiatric measure-
ments should use a more detailed cognitive assessment.
The latter should unfold the MMSE single measure into
contributing subfactors so that the specific cognitive effects
of treatment become available. Such widened cognitive
assessment would offer an array of testable correlations
between the spectrum of cognitive measurements and the
spectrum of neurophysiological measurements, thereby
possibly enhancing the agreement between measurements.
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